Author:
Pearson Andrew DJ,DuBois Steven G.,Macy Margaret E.,de Rojas Teresa,Donoghue Martha,Weiner Susan,Knoderer Holly,Bernardi Ronald,Buenger Vickie,Canaud Guillaume,Cantley Lewis,Chung John,Fox Elizabeth,Friend John,Glade-Bender Julia,Gorbatchevsky Igor,Gore Lia,Gupta Abha,Hawkins Douglas S.,Juric Dejan,Lang Leigh Anna,Leach Danielle,Liaw Danny,Lesa Giovanni,Ligas Franca,Lindberg Gavin,Lindberg Wendy,Ludwinski Donna,Marshall Lynley,Mazar Andrew,McDonough Joe,Nysom Karsten,Ours Christopher,Pappo Alberto,Parsons D.William,Rosenfeld Amy,Scobie Nicole,Smith Malcolm,Taylor Danielle,Weigel Brenda,Weinstein Amy,Karres Dominik,Vassal Gilles
Reference129 articles.
1. PI3K and cancer: lessons, challenges and opportunities;Fruman;Nat Rev Drug Discov,2014
2. Targeting the phosphoinositide 3-kinase pathway in cancer;Liu;Nat Rev Drug Discov,2009
3. Targeting the PI3K pathway in cancer: are we making headway?;Janku;Nat Rev Clin Oncol,2018
4. Combination Chemotherapy With or Without Temsirolimus in Treating Patients with Intermediate Risk Rhabdomyosarcoma. https://clinicaltrials.gov/study/NCT02567435. (Accessed 19 November 2023).
5. Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC) (EXIST-1). 〈https://clinicaltrials.gov/study/NCT00789828〉. (Accessed 19 November 2023).